rivastigmine

Ligand id: 6602

Name: rivastigmine

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: rivastigmine

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 3
Hydrogen bond donors 0
Rotatable bonds 6
Topological polar surface area 32.78
Molecular weight 250.17
XLogP 2.78
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

References
1. Birks J, McGuinness B, Craig D. (2013)
Rivastigmine for vascular cognitive impairment.
Cochrane Database Syst Rev5: CD004744. [PMID:23728651]
2. Henderson EJ, Lord SR, Brodie MA, Gaunt DM, Lawrence AD, Close JCT, Whone AL, Ben-Shlomo Y. (2016)
Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial.
The Lancet Neurology,  Online First.
3. Luo W, Yu QS, Kulkarni SS, Parrish DA, Holloway HW, Tweedie D, Shafferman A, Lahiri DK, Brossi A, Greig NH. (2006)
Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine.
J. Med. Chem.49 (7): 2174-85. [PMID:16570913]